- Home
- OTLY vs TRVI Comparison
OTLY vs TRVI Comparison
Compare OTLY & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLY
- TRVI
- Stock Information
- Founded
- OTLY 1994
- TRVI 2011
- Country
- OTLY Sweden
- TRVI United States
- Employees
- OTLY N/A
- TRVI N/A
- Industry
- OTLY Packaged Foods
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- OTLY Consumer Staples
- TRVI Health Care
- Exchange
- OTLY Nasdaq
- TRVI Nasdaq
- Market Cap
- OTLY 395.7M
- TRVI 363.7M
- IPO Year
- OTLY 2021
- TRVI 2019
- Fundamental
- Price
- OTLY $7.95
- TRVI $4.60
- Analyst Decision
- OTLY Buy
- TRVI Strong Buy
- Analyst Count
- OTLY 4
- TRVI 8
- Target Price
- OTLY $1.20
- TRVI $9.31
- AVG Volume (30 Days)
- OTLY 312.6K
- TRVI 739.7K
- Earning Date
- OTLY 02-12-2025
- TRVI 03-19-2025
- Dividend Yield
- OTLY N/A
- TRVI N/A
- EPS Growth
- OTLY N/A
- TRVI N/A
- EPS
- OTLY N/A
- TRVI N/A
- Revenue
- OTLY $823,666,000.00
- TRVI N/A
- Revenue This Year
- OTLY $9.21
- TRVI N/A
- Revenue Next Year
- OTLY $7.02
- TRVI N/A
- P/E Ratio
- OTLY N/A
- TRVI N/A
- Revenue Growth
- OTLY 5.15
- TRVI N/A
- 52 Week Low
- OTLY $6.00
- TRVI $2.30
- 52 Week High
- OTLY $26.80
- TRVI $5.05
- Technical
- Relative Strength Index (RSI)
- OTLY 33.58
- TRVI 62.80
- Support Level
- OTLY $6.00
- TRVI $3.93
- Resistance Level
- OTLY $10.90
- TRVI $4.14
- Average True Range (ATR)
- OTLY 1.40
- TRVI 0.29
- MACD
- OTLY -0.28
- TRVI 0.06
- Stochastic Oscillator
- OTLY 30.95
- TRVI 64.82
About OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.